Stay updated with breaking news from Pharming Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pharming Group (OTCMKTS:PHGUF – Get Free Report) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 7,831,200 shares, an increase of 17.2% from the November 15th total of 6,680,500 shares. Based on an average daily volume of 100 shares, the short-interest ratio is […]
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
Dutch biopharmaceutical company Pharming Group N.V. (PHAR) announced Wednesday its plans to develop leniolisib for additional primary immunodeficiencies or PIDs beyond activated phosphoinositide 3-kinase delta syndrome or APDS.
The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, November 21,
Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. announces that it has received a Day 180 Second List of Outstanding Issues from the European Medicines Agency’s Committee for...